1 Van la Parra RF,Kuerer HM.Selective elimination of breast cancer surgery in exceptional responders:historical perspective and current trials[J].Breast Cancer Res,2016,18(1):1-8. 2 Huber S,Wagner M,Zuna I,et al.Locally advanced breast carcinoma:evaluation of mammography in the prediction of residual disease after induction chemotherapy[J].Anticancer Res,2000,20(1):553-558. 3 Keune JD,Jeffe DB,Schootman M,et al.Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer[J].Am J Surg,2010,199(4):477-484. 4 Chagpar AB,Middleton LP,Sahin AA,et al.Accuracy of physical examination,ultrasonography,and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy[J].Ann Surg,2006,243(2):257-264. 5 Hylton NM,Blume JD,Bernreuter WK,et al.Locally advanced breast cancer:MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL[J].Radiology,2012,263(3):663-672. 6 Cho N,Im SA,Park IA,et al.Breast cancer:early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging[J].Radiology,2014,272(2):385-396. 7 Wu J,Gong G,Cui Y,et al.Intratumor partitioning and texture analysis of dynamic contrast-enhanced(DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy[J].J Magn Reson Imaging,2016,44(5):1107-1115. 8 Waugh SA,Purdie CA,Jordan LB,et al.Magnetic resonance imaging texture analysis classification of primary breast cancer[J].Eur Radiol,2016,26(2):322-330. 9 Park SH,Moon WK,Cho N,et al.Diffusion-weighted MR imaging:pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer[J].Radiology,2010,257(1):56-63. 10 Wu LM,Hu JN,Gu HY,et al.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?[J].Breast Cancer Res Treat,2012,135(1):17-28. 11 Che S,Zhao X,Ou Y,et al.Role of the intravoxel incoherent iotion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer[J].Medicine(Baltimore),2016,95(4):e2420. 12 Andrade WP,Lima EN,Osório CA,et al.Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?[J].Eur J Surg Oncol,2013,39(12):1358-1363. 13 Wang Y,Zhang C,Liu J,et al.Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis[J].Breast Cancer Res Treat,2012,131(2):357-369. 14 Groheux D,Majdoub M,Sanna A,et al.Early metabolic response to neoadjuvant treatment:FDG PET/CT criteria according to breast cancer subtype[J].Radiology,2015,277(2):358-371. 15 Berg WA,Madsen KS,Schilling K,et al.Breast cancer:comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast[J].Radiology,2011,258(1):59-72. 16 Xu HB,Li L,Xu Q.Tc-99m sestamibi scintimammography for the diagnosis of breast cancer:meta-analysis and meta-regression[J].Nucl Med Commun,2011,32(11):980-988. 17 Johnson N,Sorenson L,Bennetts L,et al.Breast-specific gamma imaging is a cost effective and efficacious imaging modality when compared with MRI[J].Am J Surg,2014,207(5):698-701. 18 Guo C,Zhang C,Liu J,et al.Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis[J].Nucl Med Commun,2016,37(7):675-688. 19 Lee HS,Ko BS,Ahn SH,et al.Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients[J].Breast Cancer Res Treat,2014,145(1):91-100. 20 Mitchell D,Hruska CB,Boughey JC,et al.99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer[J].Clin Nucl Med,2013,38(12):949-956. 21 Hayashi M,Yamamoto Y,Ibusuki M,et al.Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer[J].Ann Surg Oncol,2012,19(9):3042-3049. 22 Evans A,Armstrong S,Whelehan P,et al.Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer?[J].Br J Cancer,2013,109(11):2798-2802. 23 Jing H,Cheng W,Li ZY,et al.Early evaluation of relative changes in tumor stiffness by shear wave elastography predicts the response to neoadjuvant chemotherapy in patients with breast cancer[J].J Ultrasound Med,2016,35(8):1619-1627. 24 Fujisawa T,Hirakata T,Yanagita Y,et al.The detection of pCR after PST by contrast-enhanced ultrasonography for breast cancer[J].Breast Cancer,2013,20(1):75-82. 25 Amioka A,Masumoto N,Gouda N,et al.Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy[J].Jpn J Clin Oncol,2016,46(4):303-309. 26 Tran WT,Childs C,Chin L,et al.Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy[J].Oncotarget,2016,7(15):19762-19780. 27 Dominici LS,Negron Gonzalez VM,Buzdar AU,et al.Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer[J].Cancer,2010,116(12):2884-2889. 28 Hieken TJ,Boughey JC,Jones KN,et al.Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer[J].Ann Surg Oncol,2013,20(10):3199-3204. 29 Alvarado R,Yi M,Lepetross H,et al.The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J].Ann Surg Oncol,2012,19(10):3177-3184. |